

Integrated Diagnostic Holdings plc (the “Company”) Director Appointment

1 March 2022

(Cairo and London) – The Board announces the appointment of Ms Yvonne Stillhart, as a Non-Executive Director of the Company with effect from 1 March 2022. Yvonne also joins the Audit and the Remuneration Committees.

Yvonne is a seasoned Senior Executive working with innovation and growth driven companies across a wide range of industries and geographical regions, including Europe, USA, North Africa and Sub-Sahara Africa. She has been a Non-Executive Director and Audit and Risk Committee Member for more than 12 years. She has co-founded and led as a Senior Partner a specialised private equity manager in Switzerland. For several decades Yvonne has been a senior executive leader in international businesses, private market and infrastructure investments. She is focused on business building and transformation, risk management and ESG governance.

Yvonne serves currently as a non-executive Director of UBS Asset Management Switzerland Ltd. and is the Chairperson of the South African EPE Capital Ltd. She is also on the Board of Standard Life Private Equity Trust Plc.

Yvonne holds a Director Certificate from Harvard Business School, the Corporate Risk Certificate from the DCRO Institute and the ESG Competent Boards Certificate.

Yvonne replaces James Nolan who resigned on 1 September 2021.

There are no other details that are required to be disclosed under the Financial Conduct Authority LR 9.6.13 of the Listing Rules in relation to this appointment.

—Ends—



About Integrated Diagnostics Holdings (IDH)

IDH is a leading consumer healthcare company in the Middle East and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) and Echo-Lab (Nigeria). A long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 2,000 diagnostics tests. From its base of 507 branches as of 30 September 2021, IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group's expansion plans include acquisitions in new Middle Eastern, African, and Asian markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity with a Standard Listing on the Main Market of the London Stock Exchange (ticker: IDHC) since May 2015 with a secondary listing on the EGX since May 2021 (ticker: IDHC.CA). Learn more at idhcorp.com.

The person responsible for arranging the release of this announcement is Nancy Fahmy, Investor Relations Director at IDH.

For further information please contact:

Integrated Diagnostic Holdings plc

Nancy Fahmy
Investor Relations Director

+20(0)2 3345 5530

Company Secretary:
Link Company Matters Limited

IDHLondon@linkgroup.co.uk